150 related articles for article (PubMed ID: 12014434)
1. Susceptibility of LDL to oxidation in vitro and antioxidant capacity in familial combined hyperlipidemia: comparison of patients with different lipid phenotypes.
Liu ML; Ylitalo K; Vakkilainen J; Nuotio I; Valkonen M; Lahdenperä S; Viikari J; Taskinen MR
Ann Med; 2002; 34(1):48-54. PubMed ID: 12014434
[TBL] [Abstract][Full Text] [Related]
2. Association between carotid intima-media thickness and low-density lipoprotein size and susceptibility of low-density lipoprotein to oxidation in asymptomatic members of familial combined hyperlipidemia families.
Liu ML; Ylitalo K; Nuotio I; Salonen R; Salonen JT; Taskinen MR
Stroke; 2002 May; 33(5):1255-60. PubMed ID: 11988600
[TBL] [Abstract][Full Text] [Related]
3. Circulating oxidized low-density lipoprotein and its association with carotid intima-media thickness in asymptomatic members of familial combined hyperlipidemia families.
Liu ML; Ylitalo K; Salonen R; Salonen JT; Taskinen MR
Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):1492-7. PubMed ID: 15205217
[TBL] [Abstract][Full Text] [Related]
4. Small, dense LDL and elevated apolipoprotein B are the common characteristics for the three major lipid phenotypes of familial combined hyperlipidemia.
Ayyobi AF; McGladdery SH; McNeely MJ; Austin MA; Motulsky AG; Brunzell JD
Arterioscler Thromb Vasc Biol; 2003 Jul; 23(7):1289-94. PubMed ID: 12750118
[TBL] [Abstract][Full Text] [Related]
5. Metabolism of plasma low density lipoproteins in familial combined hyperlipidaemia: effect of acipimox therapy.
Ericsson S; Eriksson M; Berglund L; Angelin B
J Intern Med; 1992 Oct; 232(4):313-20. PubMed ID: 1402634
[TBL] [Abstract][Full Text] [Related]
6. LDL particle size in familial combined hyperlipidemia: effects of serum lipids, lipoprotein-modifying enzymes, and lipid transfer proteins.
Vakkilainen J; Jauhiainen M; Ylitalo K; Nuotio IO; Viikari JS; Ehnholm C; Taskinen MR
J Lipid Res; 2002 Apr; 43(4):598-603. PubMed ID: 11907142
[TBL] [Abstract][Full Text] [Related]
7. Subclasses of low-density lipoprotein and very low-density lipoprotein in familial combined hyperlipidemia: relationship to multiple lipoprotein phenotype.
Georgieva AM; van Greevenbroek MM; Krauss RM; Brouwers MC; Vermeulen VM; Robertus-Teunissen MG; van der Kallen CJ; de Bruin TW
Arterioscler Thromb Vasc Biol; 2004 Apr; 24(4):744-9. PubMed ID: 14751815
[TBL] [Abstract][Full Text] [Related]
8. Inheritance of low density lipoprotein subclass patterns in familial combined hyperlipidemia.
Austin MA; Brunzell JD; Fitch WL; Krauss RM
Arteriosclerosis; 1990; 10(4):520-30. PubMed ID: 2369363
[TBL] [Abstract][Full Text] [Related]
9. Alpha-tocopherol supplementation decreases the oxidative susceptibility of LDL in renal failure patients on dialysis therapy.
Islam KN; O'Byrne D; Devaraj S; Palmer B; Grundy SM; Jialal I
Atherosclerosis; 2000 May; 150(1):217-24. PubMed ID: 10781654
[TBL] [Abstract][Full Text] [Related]
10. Ex vivo low-density lipoprotein oxidizability and in vivo lipid peroxidation in patients on CAPD.
Roob JM; Rabold T; Hayn M; Khoschsorur G; Resch U; Holzer H; Winklhofer-Roob BM
Kidney Int Suppl; 2001 Feb; 78():S128-36. PubMed ID: 11168998
[TBL] [Abstract][Full Text] [Related]
11. Increased plasma levels of oxysterols, in vivo markers of oxidative stress, in patients with familial combined hyperlipidemia: reduction during atorvastatin and fenofibrate therapy.
Arca M; Natoli S; Micheletta F; Riggi S; Di Angelantonio E; Montali A; Antonini TM; Antonini R; Diczfalusy U; Iuliano L
Free Radic Biol Med; 2007 Mar; 42(5):698-705. PubMed ID: 17291993
[TBL] [Abstract][Full Text] [Related]
12. Impaired insulin-stimulated glucose oxidation and free fatty acid suppression in patients with familial combined hyperlipidemia: a precursor defect for dyslipidemia?
Karjalainen L; Pihlajamäki J; Karhapää P; Laakso M
Arterioscler Thromb Vasc Biol; 1998 Oct; 18(10):1548-53. PubMed ID: 9763525
[TBL] [Abstract][Full Text] [Related]
13. How different constituents of low density lipoprotein determine its oxidizability by copper: a correlational approach.
Kontush A; Hübner C; Finckh B; Kohlschütter A; Beisiegel U
Free Radic Res; 1996 Feb; 24(2):135-47. PubMed ID: 8845914
[TBL] [Abstract][Full Text] [Related]
14. LDL physical and chemical properties in familial combined hyperlipidemia.
Hokanson JE; Krauss RM; Albers JJ; Austin MA; Brunzell JD
Arterioscler Thromb Vasc Biol; 1995 Apr; 15(4):452-9. PubMed ID: 7749856
[TBL] [Abstract][Full Text] [Related]
15. Genetic influences contributing to LDL particle size in familial combined hyperlipidaemia.
Vakkilainen J; Pajukanta P; Cantor RM; Nuotio IO; Lahdenperä S; Ylitalo K; Pihlajamäki J; Kovanen PT; Laakso M; Viikari JS; Peltonen L; Taskinen MR
Eur J Hum Genet; 2002 Sep; 10(9):547-52. PubMed ID: 12173032
[TBL] [Abstract][Full Text] [Related]
16. Associations between HDL oxidation and paraoxonase-1 and paraoxonase-1 gene polymorphisms in families affected by familial combined hyperlipidemia.
Liu ML; James RW; Ylitalo K; Taskinen MR
Nutr Metab Cardiovasc Dis; 2004 Apr; 14(2):81-7. PubMed ID: 15242240
[TBL] [Abstract][Full Text] [Related]
17. Plasma proprotein convertase subtilisin kexin type 9 levels are related to markers of cholesterol synthesis in familial combined hyperlipidemia.
Brouwers MC; Konrad RJ; van Himbergen TM; Isaacs A; Otokozawa S; Troutt JS; Schaefer EJ; van Greevenbroek MM; Stalenhoef AF; de Graaf J
Nutr Metab Cardiovasc Dis; 2013 Nov; 23(11):1115-21. PubMed ID: 23333725
[TBL] [Abstract][Full Text] [Related]
18. Lack of evidence for linkage between low-density lipoprotein subclass phenotypes and the apolipoprotein B locus in familial combined hyperlipidemia.
Austin MA; Wijsman E; Guo SW; Krauss RM; Brunzell JD; Deeb S
Genet Epidemiol; 1991; 8(5):287-97. PubMed ID: 1761202
[TBL] [Abstract][Full Text] [Related]
19. How different constituents of human plasma and low density lipoprotein determine plasma oxidizability by copper.
Spranger T; Finckh B; Fingerhut R; Kohlschütter A; Beisiegel U; Kontush A
Chem Phys Lipids; 1998 Jan; 91(1):39-52. PubMed ID: 9488998
[TBL] [Abstract][Full Text] [Related]
20. Metabolic consequences of genetic heterogeneity of lipoprotein composition (lipoprotein heterogeneity).
Brunzell JD; Chait A; Albers JJ; Foster DM; Failor RA; Bierman EL
Am Heart J; 1987 Feb; 113(2 Pt 2):583-8. PubMed ID: 3812212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
